Movement Disorders and Neuromodulation Center

Movement Disorders and Neuromodulation Center

Parkinson's Disease Clinical Trials (Not Enrolling)

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
Principal Investigator: Marta San Luciano, MD, MS
Study Contact: Ananth Mahes, [email protected]

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants
Principal Investigator: Marta San Luciano, MD, MS
Study Contact: Ananth Mahes, [email protected]

Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia (Activa PC+S)
Principal Investigator: Philip Starr, MD, PhD

Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients
Principal Investigator: Philip Starr, MD, PhD

Implantable Neurostimulator for the Treatment of Parkinson's Disease (INTREPID) 
Principal Investigator: Jill Ostrem, MD

Mindfulness-based Cognitive Therapy for People With Parkinson's Disease and Caregivers
Principal Investigator: Andreea Seritan, MD

Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease
Principal Investigator: Paul Larson, MD

The Parkinson's Progression Markers Initiative (PPMI)
Principal Investigator: Caroline Tanner, MD, PhD

A Multicenter, Prospective, Longitudinal, Digital Assessment Study of Disease Progression in Subjects With Early, Untreated Parkinson Disease (WATCH-PD)
Principal Investigator: Caroline Tanner, MD, PhD

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension (PASADENA) 
Principal Investigator: Caroline Tanner, MD, PhD

A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
Principal Investigator: Chadwick Christine, MD